To determine whether the apoptotic machinery of thyroid cancer cells is functional and could be activated for tumoricidal purposes, we examined the apoptosis induced by the cytokines TNF-a, Fas and TRAIL in thyroid cancer cell lines, NPA and SW579. Interestingly, out of these cytokines, only TRAIL was able to trigger signi®cant apoptosis. The tumoricidal eect of TRAIL was further enhanced by CHX, suggesting the presence of CHX-sensitive inhibitor(s) of apoptosis in these thyroid cancer cell lines. The anti-apoptotic proteins like FLAME-1, Bcl-2 and Bcl-xL are believed to be such CHX-sensitive inhibitors in various types of cancer cells. We, however, provide the evidence using NPA and SW579 cell lines that these proteins were not aected by the CHX treatment in thyroid cancer cells. The apoptosis of thyroid cancer cells was mediated by the classical activation of caspases that in turn activated the DNA Fragmentation Factor (DFF-45). To elucidate the role of individual caspases in TRAIL-mediated apoptosis, the inhibitory eects of several general and speci®c tetrapeptide caspase inhibitors were studied. The inhibitors of caspase-1, -6, -8, and -9 as well as general upstream inhibitors of apoptosis could dramatically inhibit TRAIL-induced apoptosis in thyroid cancer cells. Caspase-2 and -3 inhibitors, on the other hand, had no signi®cant eect. When the cells were treated with either agonistic Fas antibody (CH11) or TNF-a, no apoptotic changes were observed. The apoptosis induced by agonistic Fas Ab could be seen only after a prolonged exposure (24 h) to CHX, whereas TNF-a had no eect even in the presence of CHX. The ecacy of TRAIL was also tested on other types of thyroid cancer cells like ARO, FRO (anaplastic carcinoma) and TPC-1 (papillary carcinoma) and compared to that triggered by other death inducing cytokines FasL and TNF-a. Again TRAIL was more potent in triggering apoptosis than Fas and TNF-a. Since TRAIL is eective in selectively killing thyroid tumor cells without aecting normal thyrocytes and also does not cause organ toxicity and in¯ammation in vivo, its potential for the treatment of thyroid cancer seems very promising.
Introduction
Thyroid carcinoma has a relatively high incidence in the Middle East where its crude relative frequency has been reported as high as 10.5% in Kuwaiti females while in the US it accounts for only 1.6% of all cancers in women (Farid et al., 1994) . Papillary carcinoma accounts for 85% of dierentiated thyroid carcinomas while the remaining epithelial thyroid cell tumors are predominantly follicular carcinomas. As in most solid tumors, the malignant transformation of thyroid epithelial cells is thought to arise through multiple genetic changes involving the activation of protooncogenes and the loss of tumor suppressor genes by point mutation, gene rearrangement and deletion (Farid et al., 1994; Cerutti et al., 1996; Sherr, 1996) . Some progress has been made to elucidate the molecular mechanisms that determine thyroid tumor development and progression. The genetic alterations of several oncogenes (ras, ret, trk) and tumor suppressor genes (p53, Rb, p16/CDKN2, p21/Waf1) have been identi®ed to be involved in thyroid tumorigenesis (Shi et al., 1996; Tung et al., 1996) . It is believed that ras oncogene activation is an early speci®c event for follicular cancers whereas the rearrangements of ret and trk proto-oncogenes are speci®c for papillary carcinoma (Farid et al., 1994) .
Apoptosis is an intrinsic and fundamental biological process that plays an important role in the development of multicellular organisms and in maintaining tissue homeostasis (Steller, 1995; Jacobson et al., 1997; Ashkenazi and Dixit, 1998) . It is becoming increasingly clear that the deregulation of apoptosis is a critical component of a multi-step tumorigenesis process (Thompson, 1995; Rudin and Thompson, 1997) . Three major apoptosis-inducing cytokines have been identi®ed so far. These are tumor necrosis factor alpha (TNF-a), Fas ligand (Fas L) and tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL), which induce apoptosis through activation of death machinery by binding to their cognate death receptors (Ashkenazi and Dixit, 1998; Nagata, 1997; MacFarlane et al., 1997) . These receptors share a common domain of 80 amino acids known as the`death domain' and this domain is indispensable for the initiation of signaling cascade that results in activation of aspartate-speci®c cysteine proteases now called caspases (Alnemri et al., 1996; Ashkenazi and Dixit, 1998) . Activated caspases then bring about the signature changes of apoptosis like membrane blebbing, chromatin condensation, DNA fragmentation and cytoplasmic shrinkage by cleaving important cellular proteins (Thornberry and Lazebnik, 1998) . Little is known however, whether the apoptotic machinery of thyroid cancer cells triggered by death-inducing cytokines is operational and can be activated for tumoricidal purposes. Bretz et al. (1999) studied the eect of in¯ammatory cytokines interferon g, TNF-a and interleukin-1b on the expression of TRAIL in thyroid cancer cell line KAT5, however, the mechanism of apoptosis triggered by TRAIL was not worked out. Recently, it has been reported that protein kinase C e is able to induce apoptotic cell death of thyroid cells (Knauf et al., 1999) . In this study, we determine that the death inducing cytokines are able to trigger apoptosis in various thyroid cancer cells particularly in presence of low doses of cycloheximide. We used two thyroid cancer cell lines (NPA and SW 579) as a model to examine in detail the apoptotic signaling pathways mediated by TNF-a, Fas L, and TRAIL as well as the potential tumoricidal eects of these cytokines.
Results and Discussion

Apoptosis of thyroid cancer cells
To determine whether TRAIL, Fas or TNF-a can trigger apoptosis of thyroid cancer cells, two cell lines, A B Figure 1 Morphological evaluation of TNF-a, Fas Ab, and TRAIL induced apoptosis in NPA cells. (A) Cells growing in 24-well plates were either untreated (control, a), or treated with TNF-a (50 ng/ml, b), agonistic Fas Ab (CH11, 1 mg/ml, c), TRAIL (200 ng/ ml, d). (B) The cells were treated with CHX alone (1 mg/ml, e), or in combination with TNF-a (50 ng/ml, f), agonistic Fas Ab (g), or TRAIL (h). Cells were analysed 8 h later by phase contrast microscopy for signs of apoptosis: cell rounding up, membrane blebbing, nonadherence, and chromatin condensation. A representative ®eld of cells with the indicated treatments has been shown. Similar results with more sensitivity were obtained with SW579 cell line. A typical apoptotic cell has been marked with an arrow NPA (papillary thyroid carcinoma) and SW579 (squamous cell thyroid carcinoma) were incubated with these cytokines. As shown in Figure 1A (a ± d), characteristic cell morphological changes pertinent to apoptosis (rounding up, membrane blebbing, nonadherence, chromatin condensation and cytoplasmic shrinkage) were observed in NPA cells after TRAIL treatment. Similar morphological changes were observed in case of SW579 after treatment with TRAIL (data not shown). At least 25% of NPA cells were killed after 8 h TRAIL treatment (Figure 2 ). SW579 cells are more sensitive to TRAIL-induced apoptosis than NPA (50% of killing vs 30% after 24 h treatment). Higher dosage of TRAIL (1 mg/ml) was able to kill greater than 50% of NPA and 70% SW579 cells after 24 h (data not shown). Presence of CHX (1 mg/ml) signi®cantly enhanced TRAIL-induced apoptosis in both NPA ( Figure 1B(h) ) and SW579 cell lines as more than 80% of cells were killed after 8 h incubation with TRAIL (200 ng/ml) and 97% apoptosis after 24 h (Figure 2 ). Under the same conditions, normal thyroid follicular cells could not be killed by TRAIL (Bretz et al., 1999 , and data not shown). Signi®cant apoptotic changes were not noted when thyroid cancer cells (NPA and SW 579 in particular) were treated with either TNF-a or agonistic Fas Ab (CH11) alone. However, Fas Ab in combination with CHX could induce apoptosis only after 24 h ( Figure  2 ). Increasing the dosage of agonistic Fas Ab up to 3 mg/ml did not increase substantially its killing eciency (data not shown). In contrast, TNF-a had no apoptotic eect even in the presence of CHX for 24 h in NPA and SW579 cells (Figures 1B(f) and 2). The ecacy of TRAIL-mediated killing was also tested in other types of thyroid cancer cells like ARO, FRO (anaplastic carcinomas) and TPC-1 (papillary carcinoma). Again TRAIL was more potent than Fas and TNF-a in triggering apoptosis in these cell lines after 12 h and the apoptosis was enhanced in presence of cycloheximide ( Figure 3 ). In presence of cycloheximide, TRAIL was able to trigger signi®cant apoptosis in these cells within 8 h whereas both Fas and TNF-a failed to do so and took 12 h for the same extent of killing (data not shown). This may be due to presence of dierent inhibitors of apoptosis in TRAIL-activated cell killing pathway than those of Fas and TNF-atriggered cell death pathways. It may be worth mentioning that the background killing in these cells by incubation with cyloheximide was within 5% in 8 h and around 20% after 12 h.
Caspase activation and cleavage of DFF
Since caspases play a central role in mediating apoptotic signals and are responsible for the characteristic morphological changes of apoptotic cells (Ashkenazi and Dixit, 1998; Thornberry and Lazebnik, 1998) , we therefore analysed whether the activation of caspases leads to TRAIL-induced apoptosis of thyroid tumor cells. The activation of executioner caspases like caspase-3 and -7 were studied in detail in two thyroid cancer cell lines NPA and SW579 treated with TNF-a, agonistic Fas Ab or sTRAIL in the presence of CHX for 8 h. As shown in Figure 4a , only TRAIL-induced apoptosis could activate caspase-3 and -7, as demonstrated by the signi®cant conversion of procaspases to their active subunits. Less activation of these caspases was observed in the cells treated with TRAIL alone after 8 h whereas no activation of caspases occurred with agonistic Fas Ab or TNF-a (data not shown). We next examined the expression pro®le of DNA fragmentation factor (DFF), the cleavage of which is necessary for the activation of the caspase-activated DNase that is responsible for DNA fragmentation during apoptosis (Liu et al., 1997; Enari et al., 1998) . As expected, a signi®cant DFF cleavage was found only in cells exposed to TRAIL (Figure 4a ).
Since CHX greatly enhanced the apoptotic eect of TRAIL (Figures 2 and 3) , we studied the eect of CHX a b Figure 4 Caspase activation and DFF cleavage in TNF-a, Fas Ab, and TRAIL induced apoptosis. (a) NPA and SW579 cells were treated with TNF-a (50 ng/ml), agonistic Fas Ab (1 mg/ml), and sTRAIL (200 ng/ml) in the presence of CHX (1 mg/ml). The cells were collected 8 h after the treatment, lysed, and subjected to SDS ± PAGE. Caspase activation and DFF cleavage were analysed with speci®c antibodies by Western blot. The precursor proteins and the active subunits/cleaved products have been indicated. The actual protein loading was monitored by the expression of b-actin. (b) Caspase-9 activation in TRAIL-induced apoptosis increases in the presence of CHX. NPA and MCF-7 cells were treated with sTRAIL (200 ng/ml) for 8 h in the presence or absence of CHX (1 mg/ml) as indicated. The lysates were checked for caspase-9 activation by Western blot analysis on the activation of upstream caspases like caspase-8 and -9. Accordingly NPA cells were treated with sTRAIL in the presence or absence of CHX for 8 h. MCF-7, a TRAIL-sensitive cell line was used as a positive control. As shown in Figure 4b , caspase-9 activation in NPA was higher in the presence of CHX after 8 h. The increase in the activation of caspase-9 can be judged by the appearance of p37 band of caspase-9 (Figure 4b ) that results from cleavage of caspase-9 at Asp 330 by active caspase-3 (Srinivasula et al., 1998) . Similar acceleration in caspase-8 activation was also observed after TRAIL treatment in combination with cycloheximide (data not shown). Thus the CHXsensitive inhibitor may be exerting its inhibitory eect by not allowing the activation of caspase-8 and -9.
Attenuation of apoptosis by caspase inhibitors TRAIL-induced apoptotic signal has been shown to be mediated through caspases. It is widely believed that the ligation of TRAIL leads to activation of initiator caspase-8 and probably caspase-10 through oligomerization process. The activated caspase-8 then either processes downstream procaspases like caspase-3, -6 and -7 or activates the mitochondrial pathway by cleaving BID. Cleaved BID is then transported to the mitochondria that somehow results in the leakage of cytochrome C to cytosol (Luo et al., 1998; Li et al., 1998) . The cytosolic cytochrome C unfolds Apaf-1 CARD (caspase recruitment domain) which then binds procaspase-9 and activates it to mature caspase-9 by oligomerization (Li et al., 1997; Srinivasula et al., 1998) . The activated caspase-9 also processes the executioner procaspases like caspase-3, and -7 that then cleave their respective substrates to bring about the signature changes of apoptosis. To elucidate the role of individual caspases in TRAIL-mediated apoptosis, we incubated NPA and SW579 cell lines with tetra-peptide caspase inhibitors in the presence of TRAIL and CHX for 24 h. As shown in Figure 5 , the inhibitors of caspase-1, -6, -8, and -9 as well as general upstream inhibitors of apoptosis had profound positive eect on the tumor cell survival. On the other hand inhibitors of caspase-2 and -3 had no signi®cant anti-apoptotic eect despite the fact that caspase-2 (data not shown) and caspase-3 were activated in TRAIL-induced apoptosis (Figure 4 ). This may explain the scenario where multiple execution pathways mediated by caspases are operating in transducing the apoptotic signals and inhibition of one pathway allows the other to operate without any intervention. For example the role played by caspase-3 in mediating apoptosis may be taken over by caspase-7 in the presence of caspase-3 inhibitor and vice versa. However, since activation of upstream caspases such as caspase-8 and -9 is a prerequisite of TRAIL-induced apoptosis, the inhibitors of these caspases have substantial eect on the activity of TRAIL. It is interesting to note that caspase-1 could also play a role in TRAIL mediated apoptosis in thyroid tumors, as the role of this caspase in other tumor types has not been reported. The upstream caspase inhibitor Z-VAD FMK was able to inhibit the TRAIL mediated apoptosis in other thyroid cancer cells (Figure 3 ) suggesting that caspases play universally central role in transducing apoptotic signals in thyroid cancer cells.
Cycloheximide has no effect on the expression of known apoptosis-inhibitory proteins TRAIL-induced apoptosis was signi®cantly enhanced by the presence of CHX, suggesting CHX-sensitive inhibitor(s) of apoptosis is present in the thyroid cancer cells. The anti-apoptotic proteins Bcl-2 and Bcl-xL have been shown to protect cells from apoptosis induced by TNF-a, FasL and TRAIL (Adams and Cory, 1998). However, there have been con¯icting reports about the involvement of FLAME-1 (Sriniva- Grith et al. (1998) reported decreased intracellular concentrations of FLAME-1 in melanoma cells upon incubation with TRAIL in the presence of actinomycin D whereas no such change in its expression was noticed by Zhang et al. (1999) in the same cells. It has also been suggested that FLAME-1 undergoes cleavage to inhibit apoptosis induced by FasL (Scadi et al., 1999) . Hence, we decided to check whether the potentiating eect of CHX on TRAILinduced apoptosis is indeed re¯ected by changes in the intracellular levels of these anti-apoptotic proteins. As shown in Figure 6a ,b, the expression levels of FLAME-1, Bcl-2 and Bcl-xL proteins did not change in thyroid cancer cells regardless of the CHX treatment. It has been demonstrated in some cell types that caspase 3 cleaves Bcl-2 to overcome its anti-apoptotic property (Cheng et al., 1997) . However, we could not detect such a cleavage in thyroid cancer cells (Figure 6b ). Thus the possibility of FLAME-1, Bcl-2, and Bcl-xL being the CHX-sensitive inhibitors of TRAIL-induced apoptosis may be ruled out in thyroid tumor cells. We noticed, however, that the level of Bcl-2 protein was much higher in NPA and SW579 than MCF-7, and NPA has higher Bcl-2 expression than SW579 ( Figure  6b ). The role of higher Bcl-2 protein level in inhibiting TNF-a, Fas and TRAIL-induced apoptosis in thyroid cells needs further investigation as Bcl-2 inhibits multiple pathways of apoptosis (Adams and Cory, 1998) . Accordingly, higher Bcl-2 level in NPA may be responsible for its relative resistance to TRAILmediated cell death than SW579 (Figure 2 ).
Surface expression of Fas and TRAIL receptors
We next studied the surface expression of Fas and TRAIL receptors by¯ow cytometry to evaluate if the sensitivity and resistance pro®le of the cancerous thyroid cells is due to the dierences in the expression of surface receptors. As shown in Figure 7a , the surface expression of Fas and TRAIL receptors is comparable in NPA, which may explain why NPA is sensitive to Fas Ab after 24 h treatment with CHX. The surface expression of Fas in SW579 is low as compared to TRAIL receptors whereas there was undetectable level of TNF-RI surface expression (data not presented) which may explain why these cells were not sensitive to TNF-a even in presence of cycloheximide. Four kinds of TRAIL receptors have been identi®ed so far (Ashkenazi and Dixit, 1998) : the death inducing receptors TRAIL R1 (DR4) and TRAIL R2 (DR5), and decoy receptors TRAIL R3 (DcR1) and TRAIL R4 (DcR2). Since TRAIL conveys the signal through TRAIL R1 and TRAIL R2 and is unable to do so after binding to TRAIL R3 and TRAIL R4, we were interested in studying the expression pro®le of individual receptors in NPA and SW579 by¯ow cytometry to ®gure out the role of death vs decoy receptors in transducing or blocking the death signal triggered by ligation of TRAIL. As shown in Figure  7b , the overall expression of death receptors TRAIL R1 and TRAIL R2 is higher than that of decoy receptors TRAIL R3 and TRAIL R4 in these cell lines, particularly in NPA. However, the expression pro®le of the death vs decoy receptors of TRAIL in these thyroid cell lines did not follow the apoptotic potency of TRAIL as SW579 cells were more sensitive to TRAIL than NPA (see Figure 2) . Therefore, in addition to these death and decoy receptors, the inhibitors of apoptosis may play signi®cant role in the apoptotic signaling of TRAIL in thyroid cells.
In conclusion we have shown for the ®rst time that TRAIL-mediated apoptosis is the only physiologically relevant killing pathway functioning in thyroid cancer cells and, therefore, could be exploited for tumoricidal purposes. FasL exerts its eect only after a long (24 h) a b Figure 6 Eect of cycloheximide on the expression of apoptosis inhibitory proteins. (a) NPA and SW579 cells were either untreated (control) or treated with TNF-a (50 ng/ml), agonistic Fas Ab (1 mg/ml) and sTRAIL (200 ng/ml) in the presence of CHX (1 mg/ml). The expression of anti-apoptotic proteins FLAME-1/FLIP and Bcl-xL was analysed by Western blot after 8 h treatment using speci®c antibodies. (b) The expression of antiapoptotic proteins FLAME-1/FLIP and Bcl-2 in NPA and SW579 cells in the presence or absence of CHX. Cells were either untreated (control) or treated with sTRAIL in the presence or absence of CHX for 8 h. The lysates of breast adenocarcinoma cell line MCF-7 was loaded for comparison. The expression pro®le of FLAME-1/FLIP and Bcl-2 was detected by Western blot using speci®c antibodies. The actual protein loading was monitored by the expression of b-actin TRAIL-induced apoptosis of thyroid cancer cells M Ahmad and Y Shi co-exposure with protein synthesis inhibitor CHX whereas TNF-a has no eect in inducing apoptosis even in the presence of CHX. We also established that the death signal of TRAIL in thyroid cancer cells is mediated through the activation of caspases. We provide evidence that the anti-apoptotic proteins, thought to act as cycloheximide-sensitive inhibitors in other cell lines, may not play important role in thyroid cancer cells. Despite the presence of yet undiscovered CHX-sensitive inhibitor, TRAIL-induced death pathway is still the most eective in killing thyroid tumor cells in vitro. Given that TRAIL does not cause toxicity and in¯ammation in vivo unlike Fas and TNF-a (French and Tschopp, 1999; Walczak et al., 1999) , its potential for the treatment of thyroid cancer seems very promising.
Materials and methods
Cell lines and cell culture
The human papillary thyroid carcinoma cell lines NPA, TPC-1 and anaplastic thyroid cell lines ARO and FRO were a kind gift from James A Fagin (University of Cincinnati Medical Center, Cincinnati, OH, USA) and obtained through Prof Alfredo Fusco of Universita di Reggio Calabria, Catanzaro, Italy. SW579, a squamous thyroid carcinoma cell line and MCF-7, a breast adenocarcinoma cell line were obtained from ATCC (Manassas, VA, USA). The NPA and SW579 cells were cultured in a medium containing 50% Ham's F-12 medium and 50% Dulbecco's modi®ed Eagle's medium (DMEM) with 10% fetal calf serum, penicillin (100 u/ml), streptomycin (100 mg/ml), and fungizone (25 mg/ ml) at 378C in a humidi®ed atmosphere containing 5% CO 2 . MCF-7 cells were maintained in RPMI medium whereas ARO, FRO and TPC-1 cells were grown in DMEM with same supplements as described above.
Morphological evaluation of apoptosis
Around 10 5 cells were cultured in 24-well plates overnight and were either untreated (control), or treated with TNF-a (50 ng/ml; Boehringer Mannheim, Mannheim, Germany), agonistic Fas Ab (CH11, 1 mg/ml; MBL, Nagoya, Japan), FPLC-puri®ed soluble recombinant TRAIL (200 ng/ml) in the absence or presence of CHX (1 mg/ml; Sigma, St. Louis, MO, USA). Cells were analysed 8 or 24 h later by phase contrast microscopy for signs of apoptosis like cell rounding up, membrane blebbing, nonadherence, chromatin condensation, and cytoplasmic shrinkage as described before (MacFarlane et al., 1997) . The percentage of apoptotic cells was calculated by trypan blue exclusion assay as described recently (Burow et al., 1998) and con®rmed by TUNEL assay following the recommendations of the manufacturer (Roche Molecular Biochemicals, Indianapolis, IN, USA).
Inhibition of apoptosis by caspase inhibitors
Cells were plated in 24-well plates and were either untreated , Z-Leu-Glu(OMe)-His-Asp(Ome)-¯uoromethyl ketone (Z-LEHD-FMK, caspase-9 inhibitor). Cells were analysed 24 h later and apoptotic cells were counted by trypan blue exclusion or TUNEL assay as described above.
Western blot analysis
Cells plated in 100-mm 2 culture dishes were harvested after the desired treatments and lysed in lysis buer (50 mM TrisHCl pH 7.4) containing 0.1% NP40 and a cocktail of protease inhibitors as described before (Li et al., 1998) . The lysed cells were centrifuged at 14 000 g for 15 min at 48C to remove cellular debris. Soluble protein extracts were separated by SDS ± PAGE, transferred to PVDF membrane (BioRad, Melville, NY, USA), and analysed using anticaspase-2, -3 and -7 antibodies (Transduction Laboratories, Lexington, KY, USA), anti-FLIP/FLAME-1 (CalbiochemNovabiochem Corp., La Jolla, CA, USA), anti-b-actin (clone AC-15, Sigma, St. Louis, MO, USA), anti-Bcl-2 and Bcl-xL antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Caspase-8 and -9 antibodies were a generous gift from Dr Yuri Lazebnik (Cold Spring Harbor Laboratory, New York, NY, USA). Immunoreactive bands were visualized using the enhanced chemiluminescence detection reagents (Amersham, Arlington Heights, IL, USA) according to the manufacturer's protocol.
Flow cytometry
Surface expression of Fas and TRAIL receptors on NPA and SW579 cells was determined by¯ow cytometric analysis essentially as described by Grith et al. (1998) . Brie¯y, 2610 6 cells were plated and grown for 24 h. Cells were then incubated with 2 mg/ml each of anti-Fas antibody (CH11) and T7-TRAIL in 3% BSA in PBS (PBSA) for 30 min on ice. Following three washes with PBS, cells previously incubated with T7-TRAIL were incubated with a mouse anti-T7 monoclonal Ab (Novagen Inc., Madison, WI, USA; diluted 1 : 5000 in 3% PBSA) for 30 min on ice. Finally, after three washes in PBS, the cells were stained for 30 min on ice with a goat anti-mouse FITC-conjugated Ab (1/200 dilution in 3% PBSA, Sigma, St. Louis, MO, USA). The cells were throughly washed three times in PBS. The surface expression of individual TRAIL receptors was done as above using polyclonal receptor-speci®c antibodies (purchased from R&D Systems, Minneapolis, MN, USA). After washings the cells were stained with the anti goat FITC-conjugated Ab (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) for 30 min followed by three washings as above. The cells were then analysed on a FACScan (Becton Dickinson, San Jose, CA, USA). Isotypic antibodies were used as controls.
Abbreviations sTRAIL, soluble tumor necrosis factor-related apoptosisinducing ligand; TNF-a, tumor necrosis factor-a; CHX, cycloheximide; DFF, DNA fragmentation factor; FLAME, FADD-like anti-apoptotic molecule.
